- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.09. | Polyrizon reports positive preclinical results for nasal allergy blocker | 1 | Investing.com | ||
| 12.09. | Polyrizon meldet positive präklinische Ergebnisse für nasalen Allergie-Blocker | 1 | Investing.com Deutsch | ||
| 12.09. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 100 | GlobeNewswire (Europe) | Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 14.08. | Polyrizon regains compliance with Nasdaq listing requirements | 2 | Investing.com | ||
| 14.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 14.08. | Polyrizon Ltd.: Polyrizon Regains Compliance with Nasdaq Listing Requirements | 282 | GlobeNewswire (Europe) | Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 31.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews | ||
| 22.07. | Polyrizon-Aktie steigt nach positiven Studiendaten für Allergie-Nasenspray stark an | 4 | Investing.com Deutsch | ||
| 22.07. | Polyrizon stock soars after promising nasal allergy blocker test results | 5 | Investing.com | ||
| 22.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | Polyrizon meldet vielversprechende Ergebnisse für nasalen Allergenblocker | 2 | Investing.com Deutsch | ||
| 22.07. | Polyrizon's nasal allergy blocker shows promising deposition results | 1 | Investing.com | ||
| 22.07. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 151 | GlobeNewswire (Europe) | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 16.07. | Polyrizon Stock Slides After Hours After 52% Surge On Tuesday: Why It Moved | 1 | Benzinga.com | ||
| 15.07. | Polyrizon Shares Jump Over 38% After Securing Nasdaq Listing Extension | 2 | RTTNews | ||
| 15.07. | Polyrizon retains Nasdaq listing following hearings panel | 2 | Seeking Alpha |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,905 | +1,16 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
| NOVAVAX | 7,276 | +2,48 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| 4SC | 0,952 | -1,86 % | HV-Termine: Hauptversammlungen u.a. bei 4SC, Bastei Lübbe, Janosch, Koch, mVISE, One Touch Football | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,950 | +5,98 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end
Completed design verification (DV) testing... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,140 | -0,93 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| XOMA ROYALTY | 31,600 | +1,28 % | XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. | EMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| PHIO PHARMACEUTICALS | 2,090 | -2,34 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Future Conference | King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 1,210 | -4,35 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| UNITY BIOTECHNOLOGY | 0,053 | 0,00 % | UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates | SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF | Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also... ► Artikel lesen | |
| SERES THERAPEUTICS | 14,920 | +0,27 % | XFRA 1S90: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen POLYRIZON LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,040 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.